Clinical trials: Chronic Thromboembolic Disease
Pulmonary Hypertension
BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension
Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348) will be asked to participate in this long term extension study with BAY63-2521.
- Trial name
- CHEST-2 (NCT00910429)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 73 sites in United States, Argentina and 24 more
- Volunteers
- 237 people
- Sponsor
- Bayer
Thrombosis
A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.
- Trial name
- NCT02981472
- Testing
- Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH)
- Where
- 46 sites in United States, Argentina and 12 more
- Volunteers
- 192 people
- Sponsor
- Bristol-Myers Squibb
Hypertension
Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.
It is hypothesised that ambrisentan may provide benefit to subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), where currently no proven or licensed treatment options exist.
- Trial name
- AMBER I (NCT01884675)
- Testing
- Ambrisentan 5 mg
- Where
- 51 sites in United States, Argentina and 14 more
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
Pulmonary Hypertension
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
- Trial name
- CHEST-1 (NCT00855465)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 89 sites in United States, Argentina and 24 more
- Volunteers
- 262 people
- Sponsor
- Bayer
End-stage Renal Disease, Prevention of Thromboembolic Events
Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis
In this study researchers want to learn about the safety of drug Osocimab at lower-dose and higher-doses in adult participants with kidney disease undergoing regular dialysis (a procedure that uses a machine to get rid of toxins…
- Conditions
- End-stage Renal Disease, Prevention of Thromboembolic Events, Hemodialysis, Hemodiafiltration
- Trial name
- CONVERT (NCT04523220)
- Testing
- BAY1213790 (Osocimab)
- Where
- 151 sites in United States, Australia and 17 more
- Volunteers
- 704 people
- Sponsor
- Bayer
Hypertension, Pulmonary
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
The aim of the study is to assess safety, tolerability and clinical effects of different doses of riociguat in patients with inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and who are not satisfactorily treated…
- Trial name
- EAS (NCT01784562)
- Testing
- Adempas (Riociguat, BAY63-2521)
- Where
- 102 sites in United States, Austria and 18 more
- Sponsor
- Bayer
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.
The aim of the trial is to study the long-term safety of macitentan and to provide continued treatment with macitentan to patients with pulmonary arterial hypertension (PAH) and Chronic thromboembolic pulmonary hypertension…
- Trial name
- UMBRELLA (NCT03422328)
- Testing
- macitentan
- Where
- 34 sites in Belarus, Belgium and 5 more
- Volunteers
- 151 people
- Sponsor
- Actelion
Pulmonary Hypertension
Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
The present trial investigates the long-term safety, tolerability and efficacy of bosentan in patients with inoperable CTEPH.
- Trial name
- BENEFIT OL (NCT00319111)
- Testing
- bosentan
- Volunteers
- 151 people
- Sponsor
- Actelion
Hypertension, Pulmonary
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
The purpose of the study is to enable participants with pulmonary hypertension (PH) currently treated with study intervention(s) in a clinical study (parent studies [NCT03422328, NCT03904693,NCT04565990, NCT02932410, NCT03492177…
- Trial name
- PLATYPUS (NCT05179876)
- Testing
- Macitentan, Selexipag, Macitentan/Tadalafil FDC
- Where
- 45 sites in Belarus, Belgium and 11 more
- Volunteers
- 280 people
- Sponsor
- Actelion
Hypertension, Pulmonary
An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension
This is a study to demonstrate the feasibility of an individual dose titration scheme based on the systolic blood pressure with a dose range from 1.0 mg TID to 2.5 mg TID.
- Trial name
- NCT00454558
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 15 sites in Germany
- Volunteers
- 75 people
- Sponsor
- Bayer
Hypertension, Pulmonary
Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )
This local, prospective, non-interventional, multi-center study includes patients treated with Riociguat for inoperable CTEPH(Chronic thromboembolic pulmonary hypertension)/ persistent or recurrent CTEPH after surgical treatment.
- Trial name
- JPMS-CTEPH (NCT02117791)
- Testing
- Riociguat (ADEMPAS, BAY63-2521)
- Where
- Japan
- Volunteers
- 1,298 people
- Sponsor
- Bayer
Atrial Fibrillation, Atrial Flutter
Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation
The purpose of this research study is to test an experimental drug ATI-5923 vs Coumadin. The study is intended to demonstrate ATI-5923 is superior to Coumadin for keeping INR values in the desired therapeutic range.
- Conditions
- Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction
- Trial name
- EmbraceAC (NCT00691470)
- Testing
- ATI-5923, Coumadin (warfarin)
- Where
- 41 sites in United States
- Volunteers
- 600 people
- Sponsor
- ARYx Therapeutics
Thromboembolism, Thrombosis
Tecarfarin Anti-Coagulation Trial (TACT)
TACT is a "real world" randomized controlled trial of tecarfarin, a novel vitamin K antagonist, vs. warfarin. The quality of anticoagulation control will be compared for the two groups of subjects who require chronic oral…
- Trial name
- TACT (NCT02522221)
- Testing
- Warfarin, tecarfarin
- Volunteers
- 1,000 people
- Sponsor
- Espero Biopharma
Hypertension
A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
This is an open label, long term extension to Study AMB115811. All subjects may remain in the extension study for a minimum of 18 months.
- Trial name
- AMBER II (NCT01894022)
- Testing
- Ambrisentan 5 mg
- Where
- 50 sites in United States, Argentina and 14 more
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
Hypertension, Pulmonary
This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
In this trial the effects of the inhaled drug BAY1237592 will be studied in patients with high blood pressure in the pulmonary blood vessels due to Pulmonary Arterial Hypertension (PAH) and due to Chronic Thromboembolic Pulmonary…
- Trial name
- ATMOS (NCT03754660)
- Testing
- BAY1237592
- Where
- 8 sites in Austria, Czechia and 2 more
- Volunteers
- 38 people
- Sponsor
- Bayer
Chronic Thromboembolic Pulmonary Hypertension
A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment
Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and the observed efficacy of other…
- Trial name
- SELECT (NCT03689244)
- Testing
- Selexipag
- Where
- 162 sites in United States, Argentina and 29 more
- Volunteers
- 128 people
- Sponsor
- Actelion
Hypertension, Pulmonary
A Study Investigating Routine Practice of Chronic Thromboembolic Pulmonary Hypertension Management in EMEA Countries
The aim of the registry is the assessment of the diagnosis and treatment of CTEPH (Chronic Thromboembolic Pulmonary Hypertension) in EMEA (Europe/Middle East/Africa) countries.
- Trial name
- EMEA CTEPH (NCT02637050)
- Testing
- Standard of care
- Where
- 6 sites in Kazakhstan, Kyrgyzstan and 4 more
- Volunteers
- 231 people
- Sponsor
- Bayer
Hypertension, Pulmonary
A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life…
- Trial name
- CAPTURE (NCT02545465)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 125 people
- Sponsor
- Bayer
Hypertension, Pulmonary
Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension
Evaluate the correlation between activity level (monitored by Fitbit Flex remote activity tracker) and 6-minute walk distance (6MWD) (performed by investigator) in patients with Pulmonary Arterial Hypertension (PAH) or Chronic…
- Trial name
- e-MOTION PH (NCT02536534)
- Testing
- Correlation assessment
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Bayer